Skip to content
  • RESEARCH
  • PUBLICATIONS
  • TEAM
  • LAB NEWS
  • CONTACT
  • RESEARCH
  • PUBLICATIONS
  • TEAM
  • LAB NEWS
  • CONTACT

© 2019

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.

Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L, Wang WV, Vecchione L, de Vriendt V, Weinstein BJ, Bronson RT, Tejpar S, Xavier RJ, Engelman JA, Martin ES, Hung KE.

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.

Clin Cancer Res. 2013 May 15;19(10):2688–98. PMID: 23549875, PMCID: 3815598

2014

Tags
2013

Post navigation

Previous post Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation.

Post navigation

Next post RAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
Recent Posts
  • Weight Loss and/or Sulindac Mitigate Obesity-associated Transcriptome, Microbiome, and Protumor Effects in a Murine Model of Colon Cancer
  • CAUSE, EPIDEMIOLOGY, AND HISTOLOGY OF POLYPS AND PATHWAYS TO COLORECTAL CANCER
  • SPECTROSCOPIC OPTICAL COHERENCE TOMOGRAPHY FOR CLASSIFICATION OF COLORECTAL CANCER IN A MOUSE MODEL
  • METABOLISM AND COLORECTAL CANCER
  • MIRROR MIRROR ON THE WALL, WHO IS THE FITTEST OF THEM ALL: A NOVEL PREDICTION MODEL FOR POSTOPERATIVE HEPATIC DECOMPENSATION IN PATIENTS WITH CIRRHOSIS
Archives
  • April 2023
  • January 2022
  • February 2020
  • January 2020
Categories
  • Publications
Meta
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
© 2025 Roper Labs. Created for free using WordPress and Colibri